|
Report No. : |
307046 |
|
Report Date : |
12.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
SHIJIAZHUANG LONZEAL PHARMACEUTICALS CO., LTD. |
|
|
|
|
Registered Office : |
No. 16, West Ring Road, Shenze County, Shijiazhuang, Hebei
Province, 052560 Pr |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
30.12.2006 |
|
|
|
|
Com. Reg. No.: |
130128000000119 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Subject is engaged in researching, developing and producing
pharmaceutical intermediates and APIs. |
|
|
|
|
No. of Employee : |
260 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation and expanded the daily trading band within which the RMB is permitted to fluctuate. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2013 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. Several factors are converging to slow China's growth, including debt overhang from its credit-fueled stimulus program, industrial overcapacity, inefficient allocation of capital by state-owned banks, and the slow recovery of China's trading partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated at the Communist Party's "Third Plenum" meeting in November 2013, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent in the future on fixed investments, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. The new government of President XI Jinping has signaled a greater willingness to undertake reforms that focus on China's long-term economic health, including giving the market a more decisive role in allocating resources.
|
Source
: CIA |
SHIJIAZHUANG LONZEAL
PHARMACEUTICALS CO., LTD.
NO. 16, WEST RING ROAD, SHENZE COUNTY, SHIJIAZHUANG,
HEBEI PROVINCE, 052560 PR CHINA
TEL: 86 (0) 311-87512089 FAX: 86 (0) 311-83571266
INCORPORATION DATE :
DEC. 30, 2006
REGISTRATION NO. :
130128000000119
STAFF STRENGTH :
260
REGISTERED CAPITAL : CNY 80,000,000
BUSINESS LINE :
R&D, MANUFACTURING
TURNOVER :
N/A
EQUITIES :
N/A
PAYMENT :
AVERAGE
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY
6.24 =USD 1
Adopted
abbreviations:
ANS - amount not stated NS
- not stated SC - subject company (the
company inquired by you)
NA - not available M -
million JPY –Japan Yen
SC was registered as a Limited liabilities co. at local Administration
for Industry & Commerce (AIC - The official body of issuing and renewing
business license) on Dec. 30, 2006.
Company Status: Limited Liabilities Co.
This form of business in PR China is defined as a legal person. No more
than fifty shareholders contribute its registered capital jointly. Shareholders
bear limited liability to the extent of shareholding, and the co. is liable for
its debts only to extent of its total assets. The characteristics of this form
of co. are as follows:
Upon the establishment of the co., an investment certificate is issued
to the each of shareholders.
The board of directors is comprised of three to thirteen members.
The minimum registered capital for a co. is CNY 30,000.
Shareholders may take their capital contributions in cash or by means of
tangible assets or intangible assets such as industrial property and
non-patented technology.
Cash contributed by all shareholders must account for at least 30% of
the registered capital.
Existing shareholders have pre-exemption right to purchase shares of the
co. offered for sale by the other shareholders and to subscribe for the newly
increased registered capital of the co.
SC’s registered
business scope includes developing & researching, manufacturing and selling
Lamivudine medicines intermediates; wholesale and retail of chemical products
(excluding items forbidden and limited by law, with permit if needed);
importing and exporting commodities & technologies (excluding items
forbidden and limited by law, with permit if needed).
SC is mainly
engaged in researching, developing and producing pharmaceutical intermediates
and APIs.
Mr. Wang Lixin has been legal representative and chairman of SC since
2006.
SC is known to have approx. 260 employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Shijiazhuang. Our checks
reveal that SC owns the total premise with an area of 100,000 square meters.
http://www.lonzeal.com/ The design is professional and the content is well
organized. At present the website is in both Chinese and English versions.
Email: jing@lonzeal.com
Changes
of its registered information are as follows:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registration No. |
1301282000466 |
The present one |
|
2014-4-28 |
Shareholders |
Tianjin Hengsheng International Trade Co.,
Ltd. 3.75%; Tianjin TEDA Tianheng Industry &
Trade Co., Ltd. 11.25%;
Wang Lixin 76.00%; Gu Xiaoyong 5.85%; Zheng Xiao
3.15% |
The present one |
SC’s former registered capital was CNY
15,000,000.
Organization code: 796583829
For the past two years there is no record of
litigation.
Wang Lixin
Shijiazhuang Shengze
Investment Management Center (Limited partnership)
Gu Xiaoyong
Zheng Xiao
Note: The capital contribution of SC’s
shareholders wasn’t found in local AIC.
l
Legal representative and Chairman:
Mr. Wang Lixin, born in 1968 with university education. He is currently
responsible for the overall management of SC.
Working Experience(s):
From 2006 to present Working in
SC as legal representative and chairman;
At present Also working in Tianjin TEDA
Tianheng Industry & Trade Co.,
Ltd. as legal representative.
l
General manager:
Mr. Gu Xiaoyong , born in 1970. He is currently responsible for the
daily management of SC.
Working Experience(s):
At present Working in
SC as general manager.
l
Supervisors:
Cao Yaling
Zheng Xiao
Ma Lei
l
Directors:
Gu Xiaoyong
Lv Zheng
Wang Yabin
SC is mainly
engaged in researching, developing and producing pharmaceutical intermediates
and APIs.
SC’s products mainly include:
ANTI-VIRUS
API: Lamivudine (3TC), Emtricitabine (FTC), Zidovudine (AZT),
Nevirapine (NVP), Lopinavir (RTV), Ritonavir (RTV);
ANTI-VIRUS
INTERMEDIATES: CME -
Lamivudine Intermediate,
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.43 |
|
UK Pound |
1 |
Rs.95.01 |
|
Euro |
1 |
Rs.70.63 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.